Uwe Wollina1, Leonore Unger. 1. Department of Dermatology and Allergology, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.
Abstract
BACKGROUND: Abatacept is a soluble fusion protein approved as add-on drug in rheumatoid arthritis. MAIN OBSERVATIONS: Here we report the first case of fixed drug eruption followed by lichen aureus due to abatacept in a 67-year-old woman. CONCLUSION: Fixed drug eruption is an unexpected drug reaction for abatacept, since T-cell activation is inhibited.
BACKGROUND: Abatacept is a soluble fusion protein approved as add-on drug in rheumatoid arthritis. MAIN OBSERVATIONS: Here we report the first case of fixed drug eruption followed by lichen aureus due to abatacept in a 67-year-old woman. CONCLUSION: Fixed drug eruption is an unexpected drug reaction for abatacept, since T-cell activation is inhibited.
Entities:
Keywords:
abatacept; drug reaction; lichen aureus; rheumatoid arthritis
Authors: Joel M Kremer; Harry K Genant; Larry W Moreland; Anthony S Russell; Paul Emery; Carlos Abud-Mendoza; Jacek Szechiński; Tracy Li; Julie Teng; Jean-Claude Becker; René Westhovens Journal: Arthritis Rheum Date: 2008-04
Authors: M H Buch; D L Boyle; S Rosengren; B Saleem; R J Reece; L A Rhodes; A Radjenovic; A English; H Tang; G Vratsanos; P O'Connor; G S Firestein; P Emery Journal: Ann Rheum Dis Date: 2008-09-04 Impact factor: 19.103